Jiangsu Pacific minok bio Pharmaceutical Co., Ltd
  • Meplazumab was approved for phase II/III clinical trials for the treatment of COVID-19 pneumonia by US FDA on November 13, 2020.
  • November 13,2020

  • PREVIOUS:PMBP's orphan-drug designat...
  • NEXT:Meplazumab was approved for pha...
    Stay up to date on Pacific Meinuoke
    © Pacific Meinuoke         Legal Notice       苏ICP备10218680号-1